JP2006501249A5 - - Google Patents

Download PDF

Info

Publication number
JP2006501249A5
JP2006501249A5 JP2004532301A JP2004532301A JP2006501249A5 JP 2006501249 A5 JP2006501249 A5 JP 2006501249A5 JP 2004532301 A JP2004532301 A JP 2004532301A JP 2004532301 A JP2004532301 A JP 2004532301A JP 2006501249 A5 JP2006501249 A5 JP 2006501249A5
Authority
JP
Japan
Prior art keywords
immunogen
vaccine
human
sequence
vaccine according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004532301A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006501249A (ja
Filing date
Publication date
Priority claimed from GB0220211A external-priority patent/GB0220211D0/en
Priority claimed from GB0304672A external-priority patent/GB0304672D0/en
Application filed filed Critical
Priority claimed from PCT/GB2003/003729 external-priority patent/WO2004019975A2/en
Publication of JP2006501249A publication Critical patent/JP2006501249A/ja
Publication of JP2006501249A5 publication Critical patent/JP2006501249A5/ja
Pending legal-status Critical Current

Links

JP2004532301A 2002-08-30 2003-08-28 ワクチン Pending JP2006501249A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0220211A GB0220211D0 (en) 2002-08-30 2002-08-30 Vaccine
GB0304672A GB0304672D0 (en) 2003-02-28 2003-02-28 Vaccines
PCT/GB2003/003729 WO2004019975A2 (en) 2002-08-30 2003-08-28 Il-14 vaccine for the treatment of asthma and atopic disorders

Publications (2)

Publication Number Publication Date
JP2006501249A JP2006501249A (ja) 2006-01-12
JP2006501249A5 true JP2006501249A5 (enExample) 2006-06-15

Family

ID=31980002

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004532301A Pending JP2006501249A (ja) 2002-08-30 2003-08-28 ワクチン
JP2004532296A Pending JP2006503018A (ja) 2002-08-30 2003-08-28 ワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2004532296A Pending JP2006503018A (ja) 2002-08-30 2003-08-28 ワクチン

Country Status (6)

Country Link
US (1) US20060104943A1 (enExample)
EP (2) EP1534323A2 (enExample)
JP (2) JP2006501249A (enExample)
AU (2) AU2003259374A1 (enExample)
CA (2) CA2496948A1 (enExample)
WO (2) WO2004019975A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101073590B1 (ko) * 2003-07-15 2011-10-14 메디뮨 리미티드 Il-13에 대한 인간 항체 분자
MX361174B (es) 2003-12-23 2018-11-29 Genentech Inc Anticuerpos anti-il13 novedosos y sus usos.
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20070048785A1 (en) * 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
GB0600488D0 (en) * 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
SE532249C2 (sv) * 2006-11-13 2009-11-24 Theravac Pharmaceuticals Ab Nya formuleringar av IL-18 för behandling av olika inflammatoriska sjukdomar genom vaccinering
WO2008109957A1 (en) * 2007-03-15 2008-09-18 Hunter Immunology Limited Method for determining suitability of treatment for asthma or chronic airways disease
EP2117586B1 (en) * 2007-03-15 2018-08-08 Hunter Immunology Pty Ltd Treatment or prophylaxis of asthma
SG11201601823TA (en) 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
PL3044323T3 (pl) 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
EP3574915A1 (en) * 2018-05-29 2019-12-04 Neovacs Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
AU2022215119A1 (en) * 2021-01-29 2023-08-17 Bayer Animal Health Gmbh Vaccine composition for breaking self-tolerance

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6296843B1 (en) * 1998-04-03 2001-10-02 The Penn State Research Foundation Mutagenized IL 13-based chimeric molecules
EE200100552A (et) * 1999-04-23 2002-12-16 Pharmexa A/S Meetod kasvuteguri IL-5 aktiivsuse in vivo mahasurumiseks, IL-5 analoog, seda kodeeriv nukleiinhappefragment ning kasutamine immunogeense kompositsiooni valmistamiseks
EE200200025A (et) * 1999-07-20 2003-04-15 Pharmexa A/S Meetod GDF-8 aktiivsuse allareguleerimiseks, meetod looma lihasmassi suurendamiseks, GDF-8 analoog,immunogeenne kompositsioon, nukleiinhappefragment, vektor, transformeeritud rakk ja selle valmistamismeetod, kompositsioon GDF-8 vastaste antikehadeto
WO2001034645A2 (en) * 1999-11-11 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Mutated il-13 molecules and their uses
US6846486B1 (en) * 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
IL155282A0 (en) * 2000-10-18 2003-11-23 Glaxosmithkline Biolog Sa Vaccines
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
CA2496409A1 (en) * 2002-08-30 2004-03-11 Glaxo Group Limited Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use

Similar Documents

Publication Publication Date Title
ES2257068T3 (es) Mezclas de adyuvantes de cpg y saponinas y metodos de empleo de las mismas.
Nobiron et al. Cytokine adjuvancy of BVDV DNA vaccine enhances both humoral and cellular immune responses in mice
HRP20090678T1 (hr) Cjepivo za sprječavanje i liječenje infekcije hiv-om
CA2391843C (en) Hcv vaccine compositions
JP2008531637A5 (enExample)
JP2009519309A5 (enExample)
HRP20140484T1 (hr) Cjepivni pripravci koji sadrže saponinski adjuvans
AR035586A1 (es) Composicion de vacuna, equipo, metodos para incrementar la respuesta inmune, uso de un derivado de 1h-imidazo(4,5-c)quinolin-4-amina en la fabricacion de un medicamento, y combinacion de componentes para la administracion separada, secuencial o concomitante para el uso en la vacunacion de adn
RU2015139827A (ru) МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP
ME00183B (me) Novi postupak za deregulaciju amiloida
CN1241639C (zh) 抵抗疟疾的疫苗组合物
JP2006504653A5 (enExample)
CA2704283A1 (en) Vaccine
RU2008102930A (ru) Способы введения вакцин, новые калицивирусы кошки и варианты лечения для иммунизации животных против парвовируса кошки и вируса герпеса кошки
AR053711A1 (es) Combinacion de vacunas para circovirus porcina y helicobacter y metodos de utilizacion
JP2005502314A5 (enExample)
SI2538972T1 (en) Recombinant CDV compositions and their uses
JP2006503017A5 (enExample)
AR046840A1 (es) Polisacaridos capsulares de neisseria meningitidis como inmunopotenciadores mucosales y formulaciones resultantes
Garcia et al. An updated review of ISCOMSTM and ISCOMATRIXTM vaccines
JP2012524099A5 (enExample)
Baer et al. Periodontal disease in six strains of inbred mice
CA2376926A1 (en) Use of cpg as an adjuvant for malaria vaccine
CN1338310A (zh) 一种猪瘟病毒表位疫苗及其制备方法
ES2615120T3 (es) Adyuvantes peptídicos